Gorithm showed 99.3 and 99 similarity with RMSD 0.32 and 0.65 respectively. The high percentage similarity indicates that the modeled hAChE is a better target for molecular docking as compared to torpedo enzyme. Images of modeled hAChE indicating the active site is shown in Fig 2A and 2B. Five commonly used FDA approved drugs for AD were selected and docked with the hAChE. These all turn down the breakdown of acetylcholine in the brain. This lead to increased levels of acetyl-choline in the brain, and may preserve brain function. The docking score values came out to be in the order of: Donepezil > Rivastigmine > Galantamine > Huperzine A > Tacrine. According to a Consumer Reports, when the efficiency of these treatments for AD were compared, majority of patients left tacrine treatment due to its side effects, whereas this ratio was significantly lower for donepezil and galantamine treatment. So docking score can give us an information about the efficiency of possible drug. Out of synthetically designed database hits, CID: 21158810 came out to be the highest scoring synthetic compound fulfilling the criteria of ADME. Present study showed that the hit CID: 21158810 is 81 more effective inhibitor as compared to tacrine and 19 more than that of donepezil. Moreover, the Table 1 indicates that majority of the synthetic leads are dual binding site inhibitors i.e. having two binding subunits with a chain of MEDChem Express Naringoside usually 8�C12 C atoms between individual components. These inhibitors bind to active site as well as catalytic groove of acetylcholinesterase and belong to second generation AD drugs category. As they bind the target at two sites they are more potent inhibitors. Lipinski’s rule of five is SR-9011 hydrochloride traditionally used to evaluate druglikeness or oral bioavailability of drugs in humans. It identifies five critical properties that are molecular mass <500 Da, octanol/water partition coefficient <5, number of hydrogen-bond donors <5, number of hydrogenbond acceptors <10 and molecular reactivity between 40 and 130. The rule describes molecular properties important for ADME , but, the rule does not predict pharmacological activity. It predicts high probability of clinical failure fo
